Alogliptin (NESINA), a dipeptidyl peptidase IV (DPP-4) inhibitor, was approved by the FDA on January 25, 2013 to improve blood sugar control in adults with type 2 diabetes. This drug had been ...
As shown in Figure 2 and 3, the pooled SMDs for alogliptin 12.5 mg treated vs controls, and alogliptin 25 mg treated vs controls demonstrated a significant reduction in HbA1c in patients treated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback